Get the Stockscreener App
339.30
0.56%
1.88
After Hours:
338.05
-1.25
-0.37%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $339.30, with a volume of 1.47M.
It is up +0.56% in the last 24 hours and down -1.91% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$337.42
Open:
$340.26
24h Volume:
1.47M
Relative Volume:
0.56
Market Cap:
$183.22B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
23.60
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+3.98%
1M Performance:
-1.91%
6M Performance:
+0.52%
1Y Performance:
+24.79%
1-Day Range:
$338.40
$343.80
1-Week Range:
$320.96
$343.80
52-Week Range:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
339.30 | 182.21B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen (AMGN) Announces Retirement of CFO Peter Griffith - Insider Monkey
Wealthquest Corp Acquires Shares of 3,374 Amgen Inc. $AMGN - MarketBeat
Legal & General Group Plc Boosts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by New Age Alpha Advisors LLC - MarketBeat
Simplify Asset Management Inc. Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN) Stock Analysis: Strong ROE and Promising Outlook in the Healthcare Sector - DirectorsTalk Interviews
Amgen Inc. $AMGN Shares Sold by Swedbank AB - MarketBeat
Amgen Inc. $AMGN is Smead Capital Management Inc.'s 5th Largest Position - MarketBeat
Amgen stock (US0311621009): Shares edge lower after early-February trade update - AD HOC NEWS
Amgen stock (US0311621009): earnings beat and leadership change put biotech giant in focus - AD HOC NEWS
Does Amgen’s CFO Transition and Board Structure Shape a New Governance Story for AMGN? - simplywall.st
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Legato Capital Management LLC Acquires Shares of 8,328 Amgen Inc. $AMGN - MarketBeat
Axxcess Wealth Management LLC Raises Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by Americana Partners LLC - MarketBeat
Amgen Inc. stock (US0311621009): weight-loss data and obesity ambitions move into focus - AD HOC NEWS
Amgen (NASDAQ:AMGN) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Amgen Inc. (NASDAQ: AMGN) Stock Trades Near $330 as Japan Drug Safety Crisis Raises Concerns - foreignpolicyjournal.com
Amgen Inc. stock (US0311621009): obesity data, Horizon deal and pipeline put focus back on the biote - AD HOC NEWS
Keudell Morrison Wealth Management Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Rx Rundown: Parabilis Medicines, Boston Scientific, Amgen and more - Medical Marketing and Media
Global Retirement Partners LLC Purchases 5,691 Shares of Amgen Inc. $AMGN - MarketBeat
A Look At Amgen (AMGN) Valuation As Tavneos Safety Concerns And Withdrawal Requests Escalate - Yahoo Finance
Amgen Inc. Stock 12‑Month Price Target Cut to $352.32, Implies 4% Upside - TradingView
Amgen stock (US0311621009): Q1 revenue tops estimates, CFO change keeps debt in focus - AD HOC NEWS
Amgen (AMGN) director Amy E. Miles awarded 665 RSUs, now holds 5,640 shares - Stock Titan
Amgen (AMGN) director Ellen Kullman receives 665-share RSU equity grant - Stock Titan
Amgen (NASDAQ: AMGN) director granted 665 RSUs in stock award - Stock Titan
Amgen (NASDAQ: AMGN) director granted 665-share equity award, now holds 18,284 - Stock Titan
Amgen Shareholders Reaffirm Board, Pay and Auditors - The Globe and Mail
Amgen (AMGN) director Omar Ishrak receives 665-share stock grant in Form 4 - Stock Titan
Amgen (AMGN) director Charles Holley receives 665-share RSU grant and reports 12.8K direct holdings - Stock Titan
Amgen (AMGN) director Garland receives 665 RSUs that vest immediately - Stock Titan
Amgen (AMGN) director receives 665 RSUs in immediate stock grant - Stock Titan
Amgen (NASDAQ: AMGN) director Brian Druker receives 665-share RSU grant - Stock Titan
Amgen (AMGN) director Michael V. Drake receives 665-share RSU award - Stock Titan
Amgen (AMGN) director receives 665-share RSU stock grant award - Stock Titan
Amgen’s ‘boomerang’ CFO reaps $12.5M in cash, retention bonuses - CFO Dive
Amgen Wants To Preserve Right To Seek Double Tax Relief - Law360
Amgen CFO Change Puts Focus On Debt, Growth And Capital Discipline - simplywall.st
Amgen Drug Gets New Warnings in Japan After Patient Deaths - WSJ
Amgen's Q1 earnings top estimates, 16 drugs deliver double-digit gains - MSN
CytomX Therapeutics to Present at Upcoming June Investor Conferences - GlobeNewswire Inc.
The Escalator: Amgen, CG Life, Cosette Pharmaceuticals and more - Medical Marketing and Media
IFP Advisors Inc Has $3.92 Million Stake in Amgen Inc. $AMGN - MarketBeat
Liquidity Mapping Around (AMGN) Price Events - Stock Traders Daily
Amgen Inc. (AMGN): Navellier’s Long-Term Pick on Pipeline Strength and Sales Growth - Insider Monkey
ABN Amro Investment Solutions Acquires 13,431 Shares of Amgen Inc. $AMGN - MarketBeat
AMGN Stock Price, Quote & Chart | AMGEN INC (NASDAQ:AMGN) - ChartMill
Amgen's CFO resigns – a successor has been named - medwatch.com
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):